AI assistant
Denali Therapeutics Inc. — Director's Dealing 2023
Aug 23, 2023
31637_dirs_2023-08-23_ef268591-0427-4459-88c7-6b16ff699660.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2023-08-21
Reporting Person: Krognes Steve E. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-08-21 | Common Stock | S | 1419 | $22.60 | Disposed | 145799 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 850000 | Indirect |
Footnotes
F1: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.51 to $22.99 per share. Upon request by the Commission staff, the Issuer, or a
securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 31,502 RSUs.
F4: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.